2. Academic Validation
  3. In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates

In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates

  • J Antibiot (Tokyo). 2019 Aug;72(8):600-604. doi: 10.1038/s41429-019-0188-6.
H Selcuk Ozger 1,  Tugba Cuhadar 2,  Serap Suzuk Yildiz 3 4,  Zehra Demirbas Gulmez 5,  Murat Dizbay 5,  Ozlem Guzel Tunccan 5,  Ayşe Kalkanci 2,  Husniye Simsek 3,  Ozlem Unaldi 4
Affiliations

Affiliations

  • 1 Department of Infectious Diseases and Clinical Microbiology, Gazi University School of Medicine, 06560, Ankara, Turkey. sozger@yahoo.com.
  • 2 Department of Clinical Microbiology, Gazi University School of Medicine, 06560, Ankara, Turkey.
  • 3 MoH General Directorate of Public Health, Department of National AMR Surveillance Laboratory, Ankara, Turkey.
  • 4 MoH General Directorate of Public Health, Central Laboratory, Ankara, Turkey.
  • 5 Department of Infectious Diseases and Clinical Microbiology, Gazi University School of Medicine, 06560, Ankara, Turkey.
PMID: 31028352 DOI: 10.1038/s41429-019-0188-6
Abstract

The synergistic activity of eravacycline in combination with colistin on carbapenem-resistant A. baumannii (CRAB) isolates was evaluated in this study. Minimum inhibitory concentrations (MICs) of eravacycline and colistin were determined by the broth microdilution method. MICs values ranged between 1 to 4 mg and 0.5 to 256 mg l-1 for eravacycline and colistin, respectively. In vitro synergy between eravacycline and colistin was evaluated by using the chequerboard methodology. Synergistic activity was found in 10% of the strains, and additive effect in 30%. No antagonism was detected. Similar activity was also observed in colistin-resistant CRAB isolates. The result of this study indicates that eravacycline and colistin combination may be a potential therapeutic option for the treatment of CRAB related infections.

Figures
Products